卵巢癌幸存者对治疗副作用的接受度随癌症全程中治疗目标的变化而演变
该在线调查研究纳入328名完成问卷的卵巢癌幸存者,评估其对治疗副作用的接受度是否随疾病阶段变化。当治疗目标为治愈时,超过50%的幸存者愿意耐受疲乏、脱发、腹泻等多种症状;随着目标从治愈转为缓解、再到稳定疾病,对大多数症状的耐受率显著下降。作者建议在为不可治愈患者选择药物时仔细考虑治疗毒性和生活质量影响。
要点
- 328名卵巢癌幸存者完成在线调查,35%以治愈为目标,48%以缓解为目标,17%以稳定疾病为目标。
- 以治愈为目标时,超过50%的幸存者愿意耐受疲乏(86%)、脱发(86%)、腹泻(71%)等多种症状。
- 随着治疗目标从治愈转为缓解、再到稳定疾病,对大多数症状的耐受率显著下降。
核心结论
- 卵巢癌女性在治疗目标为治愈时愿意接受许多治疗副作用,但当目标为缓解时接受度降低,目标为稳定疾病时接受度更低。
- 医生和幸存者在为不可治愈患者选择药物时必须仔细考虑治疗毒性和生活质量影响。
研究设计与样本
- 在线调查研究,通过幸存者网络和社交媒体分发问卷,聚焦幸存者的治疗目标和优先事项。
- 434名女性访问调查网站,328名(76%)完成调查。
主要发现
- 141名(43%)参与者自述曾复发,119名(36%)在完成调查时正在接受治疗,86名(26%)已接受四种或以上化疗方案。
- 治疗目标为治愈者115名(35%),缓解者156名(48%),稳定疾病者56名(17%)。
- 认为最有意义的是总生存期者148名(45%),生活质量者135名(41%),无进展生存期者40名(12%)。
- 以治愈为目标时,超过50%的幸存者愿意耐受以下症状:疲乏(283名,86%)、脱发(281名,86%)、腹泻(232名,71%)、便秘(227名,69%)、神经病变(218名,66%)、关节痛(210名,64%)、性副作用(201名,61%)、反流症状(188名,57%)、记忆丧失(180名,55%)、恶心/呕吐(180名,55%)、因治疗副作用住院(179名,55%)和疼痛(169名,52%)。
- 随着治疗目标从治愈转为缓解、再到稳定疾病,对大多数症状的耐受率显著下降。
临床怎么用
- 作者建议,在为不可治愈患者选择药物时,医生和幸存者必须仔细考虑治疗毒性和生活质量影响。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Women with ovarian cancer can have long overall survival and goals of treatment change over time from cure to remission to stable disease. We sought to determine whether survivors' acceptance of treatment side effects also changes over the disease continuum. METHODS: Women with ovarian cancer completed an online survey focusing on survivors' goals and priorities. The survey was distributed through survivor networks and social media. RESULTS: Four hundred and thirty-four women visited the survey website and 328 (76%) completed the survey. Among participants, 141 (43%) identified themselves as having ever recurred, 119 (36%) were undergoing treatment at the time of survey completion and 86 (26%) had received four or more chemotherapy regimens. Respondents' goals of care were cure for 115 women (35%), remission for 156 (48%) and stable disease for 56 (17%). When asked what was most meaningful, 148 women (45%) reported overall survival, 135 (41%) reported quality of life and 40 (12%) reported progression-free survival. >50% of survivors were willing to tolerate the following symptoms for the goal of cure: fatigue (283, 86%), alopecia (281, 86%), diarrhea (232, 71%), constipation (227, 69%), neuropathy (218, 66%), arthralgia (210, 64%), sexual side effects (201, 61%), reflux symptoms (188, 57%), memory loss (180, 55%), nausea/vomiting (180, 55%), hospitalization for treatment side effects (179, 55%) and pain (169, 52%). The rates of tolerance for most symptoms decreased significantly as the goal of treatment changed from cure to remission to stable disease. CONCLUSIONS: Women with ovarian cancer willingly accept many treatment side effects when the goal of treatment is cure, however become less accepting when the goal is remission and even less so when the goal is stable disease. Physicians and survivors must carefully consider treatment toxicities and quality of life effects when selecting drugs for patients with incurable disease.
引用
- Frey MK, Ellis AE, Koontz LM, et al. Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum. Gynecol Oncol. 2017. PMID: 28602549. doi:10.1016/j.ygyno.2017.05.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。